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Abstract. The antitumor activity of vandetanib [a multiple 
signal transduction inhibitor including the RET tyrosine 
kinase, epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor (VEGF) receptor (VEGFR), ERK 
and with antiangiogenic activity], in primary anaplastic 
thyroid cancer (ATC) cells, in the human cell line 8305C 
[undifferentiated thyroid cancer (TC)] and in an ATC-cell 
line (AF), was investigated in the present study. Vandetanib 
(1 and 100 nM; 1, 10, 25 and 50 µM) was tested by WST-1, 
apoptosis, migration and invasion assays: in primary ATC 
cells, in the 8305C continuous cell line, and in AF cells; and 
in 8305C cells in CD nu/nu mice. Vandetanib significantly 
reduced ATC cell proliferation (P<0.01, ANOVA), induced 
apoptosis dose-dependently (P<0.001, ANOVA), and inhibited 
migration (P<0.01) and invasion (P<0.001). Furthermore, 
vandetanib inhibited EGFR, AKT and ERK1/2 phosphoryla-
tion and downregulated cyclin D1 in ATC cells. In 8305C and 
AF cells, vandetanib significantly inhibited the proliferation, 
inducing also apoptosis. 8305C cells were injected subcutane-
ously in CD nu/nu mice and tumor masses became detectable 
after 30 days. Vandetanib (25 mg/kg/day) significantly inhib-
ited tumor growth and VEGF-A expression and microvessel 
density in 8305C tumor tissues. In conclusion, the antitumor 
and antiangiogenic activity of vandetanib is very auspicious in 
ATC, opening the way to a future clinical evaluation.
Introduction
Anaplastic thyroid cancer (ATC) represents ~1% of all thyroid 
cancer (TC) cases, and is one of the most aggressive human 
tumors, accounting for 15-40% of TC-related deaths (1,2). 
ATC is classified as stage Ⅳ (American Joint Committee 
on Cancer), regardless of tumor size, or presence of lymph 
node or distant metastases (present in ~80% of patients at 
diagnosis) (3-5); median survival is 6 months. The multimodal 
treatment [including debulking, chemotherapy (doxorubicin, 
cisplatin, paclitaxel or docetaxel), and hyperfractionated 
accelerated external beam radiotherapy] is the most effec-
tive treatment, with a median survival of 10 months (6,7). 
Several genetic alterations have been shown in ATC molecular 
pathways, leading to tumor aggressiveness and progression 
[p53, BRAF, RAS, RET/PTC, vascular endothelial growth 
factor (VEGF) receptor (VEGFR)-1, VEGFR-2, epidermal 
growth factor receptor (EGFR), PDGFRα, PDGFRβ, KIT, 
MET, PIK3Ca, PIK3Cb and PDK1] (7,8). New drugs targeting 
these molecular alterations have been recently evaluated in 
ATC (7), but to date no significant improvement in patient 
survival has been observed.
Vandetanib (ZD6474, Caprelsa®) is an oral once-daily 
multi-tyrosine kinase inhibitor (TKI), that inhibits the acti-
vation of RET, EGFR, VEGFR-2, VEGFR-3, and slightly 
VEGFR-1, and has potent antiangiogenic activity (9). Potent 
antineoplastic action of vandetanib was shown against 
transplantable medullary thyroid carcinoma (MTC) in nude 
mice (10). In patients with aggressive MTC, a phase Ⅲ clinical 
study showed that vandetanib improved progression-free 
survival (30.5 vs. 19.3 months in the control group) (11). It 
was approved by the Food and Drug Administration, and the 
European Medicines Agency, in 2011, to treat locally advanced 
or metastatic MTC (12). Vandetanib has also shown promising 
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results in aggressive differentiated TC patients not responsive 
to the usual therapies (13,14). In the present study, we aimed 
to evaluate the antineoplastic activity of vandetanib in ATC 
continuous cell lines, and in primary ATC cells, in vitro and 
in vivo.
Materials and methods
Drug. The effect of vandetanib (ZD6474, Caprelsa®; Aurogene 
Srl, Rome, Italy; 1 and 100 nM; 1, 10, 25 and 50 µM) was 
investigated in vitro in primary ATC cell cultures, in the 
8305C continuous cell line, and AF cells; and in vivo in 8305C 
cells in CD nu/nu mice.
Reagents. RPMI-1640 medium was obtained from Gibco 
(Thermo Fisher Scientific, Inc., Waltham, MA, USA); PCR 
reagents for quantitative real-time were obtained from 
Applied Biosystems (Thermo Fisher Scientific, Inc.). The 
other chemicals and supplements not reported in this section 
were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, 
Germany).
Patient source for thyroid tissue. We obtained surgical thyroid 
tissue samples from: i) eight ATC patients at surgery; and 
ⅱ) six healthy subjects who underwent parathyroidectomy. 
Recognized clinical, laboratory and histological criteria were 
used to establish the diagnosis (15-17). The absence of thyro-
globulin (Tg), thyroperoxidase (TPO), thyroid-stimulating 
hormone (TSH) receptor, and sodium/iodide symporter (NIS) 
expression was shown by immunohistochemistry, that was 
positive for cytokeratin (Fig. 1). DNA extraction and microdis-
section, and the detection of BRAF mutation were conducted 
by PCR Single-strand Conformation Polymorphism (by 
accepted protocols); such as direct DNA sequencing (15-17). 
All patients and controls agreed to enter the study, which was 
approved by the local Ethics Committee of the University of 
Pisa.
Primary ATC cell culture. We prepared ATC cells using 
protocols published previously (15-17). Cancer tissues were 
divided in fragments of 1-3 mm, and washed 3-5 times in 
M-199 media together with streptomycin (500,000 U/l), 
penicillin (500,000 U/l) and nystatin (1,000,000 U/l). 
Fragments were suspended in Dulbecco's modified Eagle's 
medium (DMEM) with penicillin/streptomycin (50 mg/l), 
glutamine (1% w/v) and fetal calf serum (FCS) (20% v/v) 
and then incubated at 37˚C in 5% CO2 (all were from 
Sigma-Aldrich; Merck KGaA).
As soon as the primary culture reached confluence, 
the cells were transferred into primary tissue culture 
flasks (Becton‑Dickinson Labware, Bedford, MA, USA). To 
evaluate colony‑forming efficacy, cells on their 3rd passage 
were coated in Methocel™(Dow Chemical Co., Milan, 
Italy) (18). The biggest colonies were spread in tissue-culture 
flasks (15‑17). At the 4th passage, the cells were tested. The 
absence of Tg, TSH receptor (19), NIS (20), and TPO (21) 
expression was shown by immunocytochemistry. Focal 
positivity for cytokeratin was observed by immunocytochem-
istry (20). DNA fingerprinting demonstrated a pattern similar 
to the original cancer tissue (15-17).
Thyroid follicular cell (TFC) culture. TFCs were established 
as previously reported (22).
AF cells. Among the eight primary ATC cell cultures, one (the 
AF cell line) grew >50 passages, and was also able to grow in 
nu/nu mice when subcutaneously inoculated.
8305C continuous cell line. 8305C cells (undifferentiated TC 
cell line, with papillary component; DSMZ, Braunschweig, 
Germany) were maintained in RPMI-1640 with 15% fetal 
bovine serum (FBS) with the addition of 2 mM L-glutamine.
Viability and proliferation assay. In order to investigate cell 
proliferation, we conducted a WST-1 (Roche Diagnostics, 
Almere, The Netherlands) (16,17,22). We plated TFC, ATC, AF 
and 8305C cells (at 35,000 cells/ml in 100 µl/well, of 96-well 
plates), and treated them with vandetanib or with vehicle alone 
for 24 h. To achieve IC50, the cells were treated with a concen-
tration range of vandetanib (in quadruplicate), and IC50 was 
estimated by linear interpolation. Triplicate experiments were 
conducted for each cell preparation (16,17,22). The absorbance 
was estimated at 450 nm after 1 and 2 h from the beginning of 
tetrazolium reaction.
Cell number counting was used, as well, to estimate 
the proliferation in all the considered cells, as previously 
reported (16,17,22).
Apoptosis‑Hoechst uptake. Firstly, we plated ATC, 8305C 
and AF cells (35,000 cells/ml in 100 µl/well; 96-well plates). 
Thereafter, the cells were treated for 48 h with vandetanib 
(37˚C, 5% CO2), and dyed with Hoechst 33342 as previously 
described (22). The apoptotic cells/total cells x100 ratio (apop-
tosis index) was evaluated.
Annexin V binding assay for apoptosis. The assay was carried 
out on cells seeded in Lab‑Tek Ⅱ Chamber Slide System (Nalge 
Figure 1. Immunohistochemistry for cytokeratin of anaplastic thyroid 
cancer (ATC) tissue. The presence of cytokeratin expression is shown in ATC 
cells (magnification, x400).
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Nunc International, Penfield, NY, USA), treated with vande-
tanib for 48 h, as previously reported (22).
Migration and invasion assays. A 96-well Transwell Permeable 
Support (Corning Life Sciences, Corning, NY, USA) was used 
to achieve cell migration and invasion, in agreement with 
the manufacturer's instructions, applying minor modifica-
tions (23,24).
To assess intracellular fluorescence, we used a 96-well 
plate ELISA reader (excitation at 485 nm and emission at 
520 nm). For the migration assay cells were incubated for 12 h; 
for the invasion assay, 24 h. For the invasion experiments, the 
inserts were coated with a basement membrane extract solu-
tion (Trevigen, Gaithersburg, MD, USA) overnight (37˚C, 5% 
CO2), before plating cells. For each assay we constructed a 
standard curve to transform the fluorescence data obtained to 
the number of invasive or migrated cells. All the data were 
analyzed by StatView version 5.0 (SAS Institute, Inc., Cary, 
NC, USA).
ELISA tests in ATC cells
Phospho‑EGFR inhibition cell‑based assay. ATC cells 
(5x104 cells/well) were plated in 1% FBS medium for 24 h, 
and then treated for 72 h with vandetanib at a concentration 
similar to the experimental IC50 of cell proliferation (25 µM 
for ATC), and with a higher (50 µM), or with a lower (1 µM) 
concentration of vandetanib, or with vehicle. We collected cell 
lysates as previously reported (25) and we assayed them with 
PathScan phospo-EGFR (Tyr1173) and total EGFR sandwich 
ELISA kits (Cell Signaling Technology, Inc., Danvers, MA, 
USA). Optical density (OD) was estimated at 450 nm.
AKT (pThr308), or ERK1/2 (pTpY185/187). ATC cells 
(5x104 cells/well) were exposed for 72 h to vandetanib and 
subsequently lysed (25), and tested for human AKT or ERK1/2 
phosphorylation by the PhosphoDetect AKT (pThr308) 
or by PhosphoDetect ERK1/2 (pThr185/pTyr187) ELISA 
kits (Calbiochem; EMD Millipore, Billerica, MA, USA). Data 
were normalized by total protein AKT, or ERK1/2 concentra-
tions evaluated by AKT, or ERK1/2 ELISA kits, respectively. 
OD was estimated at 450 nm.
Cyclin D1 protein expression. The ATC cells were exposed 
for 72 h to vandetanib at the above considered concentrations 
or to vehicle, in order to evaluate the vandetanib-modulated 
expression of the protein cyclin D1. Cyclin D1 protein amount 
was measured by lysing cells with (ice-cold 1X) lysis buffer 
(0.5 ml), as previously reported (25). Lysates were gathered and 
then sonicated on ice (for 10 sec). Subsequently, the samples 
were microcentrifuged at 4˚C for 10 min and the supernatant 
was gathered. Cyclin D1 was measured in cancer cell lysates 
by the human ELISA kit (Uscn Life Sciences, Inc., Wuhan, 
China). OD was measured at 450 nm, and the obtained data 
were reported as cyclin D1 ng/mg of total protein.
In vivo studies
Animals and treatment. Six-week-old CD nu/nu male mice 
weighing 20-25 g, supplied by Envigo (Milan, Italy), were 
housed in microisolator cages on vented racks and manipu-
lated using aseptic techniques and were allowed unrestricted 
access to sterile food and water. We proceeded according to the 
protocol approved by the Academic Organization Responsible 
for Animal Welfare [Organismo Preposto per il Benessere 
Animale (OPBA)] at the University of Pisa, in agreement with 
the Italian law D.lgs. 26/2014, and by the Italian Ministry of 
Health (authorization no. 613/2015-PR). In order to obtain 
statistically meaningful results, each experiment was conducted 
with the minimum necessary number of mice. In each mouse 
we inoculated, subcutaneously, 2x106±5% viable 8305C cells, 
on day 0. Animal weights were monitored, and tumor volume 
(mm3) was defined as: [(w1 x w1 x w2) x (π/6)], where w1 refers 
to the smallest tumor diameter (mm), whereas w2 to the largest 
one. We started the treatment (n=5 mice/group) after 30 days 
from cell inoculation, when the mean volume was ~100 mm3. 
All mice were randomized just before initiation of treatment. 
Control mice received vehicle alone, or 25 or 12.5 mg/kg/day 
of vandetanib, injected intraperitoneally (i.p.) for 29 days. An 
anesthetic overdose of urethan was used to sacrifice mice, and 
the tumors were then excised and measured.
Microvessel density in the cancer tissue, and immunohisto‑
chemistry. Cancer tissues from the three treatment groups 
were weighed, and then fixed in formalin and subsequently 
embedded in paraffin. The sections (5 µm) were stained with 
hematoxylin and eosin, and immunostaining was conducted 
as previously described (23). An anti-VEGF rabbit poly-
clonal antibody (diluted at 1:50; cat. no. sc-152; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA) was used to 
estimate VEGF expression, as the percentage of positive cells 
in ~1,000 tumor cells. Anti-FVIII polyclonal antibody (cat. 
no. 760-2642; Ventana Medical Systems, Inc.:Roche Group, 
Tucson, AZ, USA) was used to determine microvascular 
count (MVC), as previously described (23).
Statistical analysis. For normally distributed variables, the 
values are expressed as mean (±SD), or as median (and inter-
quartile range). Experiments were conducted thrice with ATC 
from each subject, and here we report the mean in the eight 
samples obtained by different donors (for TFC and ATC). 
One-way ANOVA, or Mann-Whitney U or Kruskal-Wallis 
test, were used to compare mean group values for normally 
distributed variables. χ2 test was applied to compare propor-
tions. Post hoc comparisons on normally distributed variables 
were conducted by Bonferroni-Dunn test. Apoptosis results 
were analyzed by one-way ANOVA with Newman-Keuls 
multiple comparisons test. All the data were analyzed by 
StatView version 5.0 (SAS Institute, Inc.).
Results
In vitro studies in primary cell cultures
Cell proliferation. Vandetanib significantly reduced ATC 
cell proliferation vs. the control, at 1 and 2 h (P<0.01, by 
ANOVA, for both) (Fig. 2A). Cell counting confirmed these 
results: after 1 h, the cell number was 12,120±680/100 µl/well 
in the ATC control group; 11,998±710 (99%) with vande-
tanib 1 nM; 11,635±780 (96%) with vandetanib 100 nM; 
10,787±690 (89%) with vandetanib 1 µM; 9,332±710 (77%) 
with vandetanib 10 µM; 8,610±580 (71%) with vandetanib 
25 µM; and 3,878±490 (32%) with vandetanib 50 µM (P<0.01, 
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ANOVA); after 2 h, cell number was 18,950±910/100 µl/well; 
18,382±920 (97%) with vandetanib 1 nM; 17,623±990 (93%) 
with vandetanib 100 nM; 14,592±1,010 (77%) with vande-
tanib 1 µM; 10,423±1,180 (55%) with vandetanib 10 µM; 
6,443±1,190 (34%) with vandetanib 25 µM; and 2,274±750 
(12%) with vandetanib 50 µM; (P<0.01, ANOVA). The IC50 
value, obtained with linear interpolation, was 13±2.9 µM for 
vandetanib.
The results of WST-1 assay in TFC cells with vandetanib 
showed a slight but significant reduction in proliferation with 
respect to the control both at 1 h (P<0.01, ANOVA) with 
vandetanib 10 µM (94% vs. control), 25 µM (87% vs. control), 
and 50 µM (81% vs. control), and at 2 h (P<0.01, for both, 
ANOVA) with vandetanib 10 µM (87% vs. control), 25 µM 
(81% vs. control), and 50 µM (76% vs. control). Cell counting 
supported the previously reported results: after 1 h, the cell 
number was 11,290±730/100 µl/well in the TFC control; 
10,612±1,080 (94%) with vandetanib 10 µM; 9,822±940 (87%) 
with vandetanib 25 µM; and 9,145±880 (81%) with vandetanib 
50 µM; (P<0.01, ANOVA); after 2 h, the cell number was 
17,950±910/100 µl/well; 15,615±1,090 (87%) with vandetanib 
10 µM; 14,540±950 (81%) with vandetanib 25 µM; and 
13,640±890 (76%) with vandetanib 50 µM (P<0.01, ANOVA).
Proliferation and BRAF. Three considered ATCs had 
V600EBRAF mutation, while RET/PTC1 and RET/PTC3, 
H-RAS or N-RAS mutations were not reported in primary 
ATC cells by real-time PCR. Proliferation was inhibited 
similarly in ATC from cancers with or without V600EBRAF 
mutation (data not shown).
Apoptosis. Vandetanib increased the number of apoptotic ATC 
cells dose-dependently (P<0.001; by ANOVA; Fig. 2B). The 
Annexin V assay corroborated these results (Fig. 2C and D).
Migration and invasion. The effect of vandetanib on migration 
and invasion was evaluated in ATC cells showing a reduction 
in both migration (Fig. 3A) and invasion (Fig. 3B).
EGFR inhibition in ATC cells by vandetanib. Vandetanib 
significantly reduced the phosphorylated (p)EGFR/total 
EGFR ratio in the ATC cell lysates in a dose-dependent 
manner (Fig. 4A).
Inhibition of AKT or ERK1/2 phosphorylation in ATC cells by 
vandetanib. Vandetanib significantly reduced the pAKT/total 
AKT and pERK1/2/total ERK1/2 protein ratios in the ATC 
cells (Fig. 4B and C).
Vandetanib decreases cyclin D1 protein levels in ATC cells. 
Lower cyclin D1 concentrations were detected in ATC 
cells treated with vandetanib vs. those treated with vehicle, 
and vandetanib inhibited cyclin D1 gene expression in a 
dose-dependent manner (P<0.05; Fig. 4D).
Figure 2. Proliferation (WST-1), and apoptosis assays in primary human anaplastic thyroid cancer (ATC) cells. (A) WST-1 in ATC cells treated with vandetanib 
for 24 h. Vandetanib significantly reduced ATC cell proliferation vs. control. Bars represent mean (±SD). *P<0.05 vs. control with Bonferroni-Dunn test. 
(B) ATC cell apoptosis after treatment with vandetanib for 48 h. Apoptosis index was determined by Hoechst staining. Vandetanib dose-dependently induced 
the percentage of apoptotic cells. Data are presented as mean (±SD) (n=8), and were analyzed by one-way ANOVA (with Newman-Keuls multiple comparisons 
test, and with a linear trend test) (*P<0.001 vs. control). (C and D) Representative images of the Annexin V binding assay in control and treated ATC cells (with 
vandetanib 50 µM), respectively.
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Studies in vitro in AF and 8305C cells. Vandetanib demon-
strated a dose-dependent antiproliferative activity in the 8305C 
cell line (IC50 of 9.6±3.4 µM) (Fig. 5A), and in AF cells (IC50 of 
4.7±1.8 µM) (Fig. 5B). Vandetanib dose-dependently induced 
the apoptosis of the 8305C cells: apoptotic cells were 16.8% 
with vandetanib 10 µM, and 20 and 33.2% with vandetanib 
25 and 50 µM, respectively (P<0.001; by ANOVA; Fig. 5C). 
In AF cells, vandetanib dose-dependently increased apop-
tosis: apoptotic cells were 19.9% with vandetanib 10 µM, and 
22.7 and 27.8% with vandetanib 25 and 50 µM, respectively 
(P<0.001; by ANOVA; Fig. 5D).
In vivo studies
Vandetanib inhibits 8305C tumor growth in mice with no body 
weight loss. Thirty days after subcutaneous xenotransplanta-
tion of 8305C cells in CD nu/nu mice, tumor masses reached 
the average volume of 100 mm3 and treatment with vandetanib 
was initiated. In order to establish the optimal antitumor dose, 
two different doses were administered. At the lower dose of 
12.5 mg/kg a slight, but not significant, antitumor activity 
was recorded (overall from days 16 to 22), and no statistical 
differences were obtained when tumor volumes in the treat-
ment group were compared to the control group (Fig. 6A). 
Figure 3. Migration and invasion tests in anaplastic thyroid cancer (ATC) cells. ATC cells were incubated for (A) 12 h for migration and (B) 24 h for invasion. 
For comparison, the inhibition of proliferation (at 12 h) (% with respect to control) and the inhibition of migration are reported in the Table in (A), and the inhi-
bition of proliferation (at 24 h) (% with respect to control) and the inhibition of invasion are shown in (B). Bars represent the mean (±SD). *P<0.05 vs. control 
(control = medium + FCS 10%) by Newman-Keuls test.
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Figure 4. Inhibition of epidermal growth factor receptor (EGFR), AKT, ERK1/2 phosphorylation, or cyclin D1 protein expression in anaplastic thyroid 
cancer (ATC) cells. (A) Inhibition of EGFR phosphorylation by vandetanib in ATC cells after 72 h of treatment. Experiments were repeated thrice, with 
eight samples (for each dose). Mean (±SE); *P<0.05 vs. control. (B and C) Inhibition of ERK1/2 (pThr185/pTyr187) and AKT (pThr308) phosphorylation 
by vandetanib in ATC cells after 72 h of treatment. Experiments were repeated, independently, thrice with eight samples (for each dose). Mean (±SE); 
*P<0.05 vs. control. (D) Cyclin D1 concentrations in ATC cells exposed to vandetanib or vehicle for 72 h. Cyclin D1 results are expressed as ng/mg of total 
protein. Experiments were repeated 6 times with eight samples (for each dose). Mean (±SE); *P<0.05 vs. control.
Figure 5. WST-1 and apoptosis assays in 8305C or AF cells. WST-1 assay results in (A) 8305C and (B) AF cells treated with vandetanib for 24 h. A sig-
nificant inhibition of proliferation vs. control is shown with vandetanib. Bars are mean (± SD). *P<0.05 vs. control with Bonferroni-Dunn test. Apoptosis in 
(C) 8305C or (D) AF cells exposed to vandetanib for 48 h [mean (±SD) of the samples]. Apoptosis index (ratio between apoptotic and total cells) x100 was 
determined by Hoechst staining. One-way ANOVA was used to analyze the data (with Newman-Keuls multiple comparisons test, and with a test for linear trend) 
(*P<0.001 vs. control). IC50 vs. controls were estimated by non‑linear regression fit (see Results); IC50 was 9.6±3.4 µM for 8305C cells, and 4.7±1.8 µM in AF cells.
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In contrast, at the highest dose of 25 mg/kg/day i.p., vande-
tanib significantly inhibited tumor growth (e.g., at day 25, 
282.1 vs. 1,086.9 mm3 of controls P<0.05; Fig. 6A). Notably, 
no loss of mouse body weight throughout the course of the 
experiment was observed at both the administered doses, 
suggesting that the vandetanib treatment was well tolerated 
even at its optimal antitumor dose (Fig. 6B).
Vandetanib decreases VEGF‑A expression and microvessel 
density in 8305C tumor tissues. 8305C cells led to the forma-
tion of a tumor histologically similar to ATC. Vandetanib 
significantly reduced VEGF‑A and FVIII immunostaining. 
A localized immunoreactivity for VEGF-A was present in 
cells of the control cancer mass, and vandetanib reduced 
it (51±9 vs. 37±7; P<0.05), with a concurrent reduction in 
microvessel density (15±4 vs. controls 26±7; P<0.05).
Discussion
Vandetanib belongs to the TKIs, that are under evaluation for 
ATC treatment (26).
With the present study, we contributed to the understanding 
of the anticancer activity of vandetanib, demonstrating that: 
i) it inhibited primary ATC cell proliferation in vitro, through 
increased apoptosis, and suppressed the migration and inva-
sion abilities as well; and ⅱ) it blocked 8305C cell proliferation 
in vitro, increasing apoptosis and reducing 8305C tumor 
growth in CD nu/nu mice as well, with no toxicity.
Our results are in line with those of another study that 
reported how vandetanib is able to inhibit 8305C cell growth 
in vivo, and to block angiogenesis, decreasing vascular perme-
ability (27). We also observed the important antiangiogenic 
activity of vandetanib in 8305C xenotransplants.
The antiproliferative action of vandetanib was observed 
in all the used primary ATC cells, independently from the 
absence/presence of V600EBRAF mutation.
Our data support the concept that vandetanib could be 
used for a multiple signal inhibition (involving RET, VEGFR, 
EGFR, ERK, AKT, and others), and it also exhibits antiangio-
genic activity (28).
It is suggested that AKT plays a crucial role in ATC onco-
genesis, and it has been demonstrated that pharmacological 
and molecular inhibition of PI3K or AKT isoforms are able 
to reduce the in vitro growth and motility of human TC cell 
lines (29,30). Moreover, both RAS/RAF/MAPK, ERK and 
PI3K pathways are implicated in the carcinogenesis of TCs, 
and mutations in such genes have been reported in ATC (31). 
Since AKT and ERK proteins are activated, once phosphory-
lated, in ATC, these proteins have been suggested as potential 
targets of therapy. In the present study in ATC cells, vandetanib 
significantly inhibited ERK1/2 and AKT phosphorylation.
Furthermore, EGFR phosphorylation in ATC cells was 
significantly reduced by vandetanib treatment, according to 
the results obtained by Di Desidero et al (32) and our previous 
results (33), reporting that TKI suppressed EGFR phosphory-
lation in ATC.
Cyclin D1 regulates cell cycle progression (34), and its 
expression was observed at different levels in ~67% of ATC 
cells by Lee et al (35). In addition, overexpression of cyclin D1 
was reported in 77% of ATC by Wiseman et al (36). Vandetanib, 
a TKI of both VEGFR-2, and EGFR, inhibited cell growth 
downregulating cyclin E and D1 expression (37). Notably, we 
showed that vandetanib downregulated the cyclin D1 protein 
in ATC cells.
We found a significant 8305C cell‑derived tumor growth 
inhibition in CD nu/nu mice by vandetanib, without body 
weight loss, suggesting a minimal toxicity profile, whereas 
other compounds are known to provoke different adverse 
effects in humans and animals (38). Nevertheless, we did not 
collect data concerning the kidney, liver, or other biochemical 
tests, that will be provided in future studies.
Antineoplastic activity of vandetanib in ATC is the result 
of different effects on tumoral cells, that include: i) antiprolif-
erative activity; ii) increased apoptosis; ⅲ) inhibition of both 
migration, and invasion; and ⅳ) inhibition of cancer neovas-
cularization.
New therapeutic attempts for the treatment of ATC are 
ongoing, even if various limitations are still present for the 
selective use of new molecules. Even if neoplastic tissue has 
a potential target (as BRAF), the tumor response is present 
in only a few patients. As we achieve target inhibition, any 
response may occur owing to the increased activity of other 
compensatory pathways, that rescue cancer cell growth. The 
efficacy of treatment could be increased by assessing the 
sensitivity of primary ATC cells from each subject to different 
TKIs. In fact, in vitro chemosensitivity tests are able to predict 
Figure 6. In vivo experiments. (A) Dose-dependent antitumor in vivo effect 
of vandetanib at the dose of 12.5 and 25 mg/kg/day intraperitoneally (i.p.), 
on 8305C tumors xenotransplanted in CD nu/nu mice. (B) Weights of mice 
monitored during the treatment with the two doses of the drug and vehicle 
alone. Symbols and bars, mean (±SE); *P<0.05 vs. vehicle-treated controls.
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in vivo effectiveness in 60% of cases (39), while a negative 
chemosensitivity test in vitro is associated with a 90% of 
ineffectiveness of the treatment in vivo (39,40), thus avoiding 
the administration of inactive chemotherapeutics to these 
patients (15,16,24,26).
In the present study, we first showed an antitumoral 
activity of vandetanib (a multi-targeted kinase inhibitor, with 
antiangiogenic effect) in human primary ATC cell cultures 
established directly from patients, paving the way for person-
alized TKI and for future clinical trials.
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